Respiratory
Conditions
Interventions
Hydrochloroquine 600 mg plus Azythromycine
Hydroxychloroquine 400 plus Azythromycine.
Zinc
Sponsors
Faculty of Medicine University Cheikh Anta Diop of Dakar Senegal.
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: (i) patients above the age of 18 with PCR confirmed covid19 infection less than 72 hours prior to randomisation,; (ii) absence danger signs such as respiratory distress requiring mechanical ventilation or supplemental oxygen encephalitic disorders, renal function failure; (iii) absence of known chronic illness.
Exclusion criteria
Exclusion criteria: (i) Known allergy to any of the study medication; (ii) pregnancy or breastfeeding; (iii) ECG abnormality at admission; (iii) Patients with ALAT/ASAT higher than 3 times the upper limit of normal on admission; (iv) Patients with known chronic kidney diseases; (v) Patients with known retinal diseases.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Percentage of patients with undetectable viral load 7 days after treatment initiation. | — |
Secondary
| Measure | Time frame |
|---|---|
| Time to first PCR negative after treatment initiation. ;Absolute and relative changes in biochemical parameters from baseline to day 7 after treatment initiation. Absolute and relative changes in haematological parameters from baseline to day 7 after treatment initiation. Proportion of participants with ECG abnormality after treatment initiation | — |
Countries
Senegal
Contacts
Public ContactCheikh T. NDOUR
Fann Teaching Hospital Division of Infectious and Tropical Diseases
Outcome results
None listed